Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249569 · ClinicalTrials.gov registry record · Phase 2
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05249569 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT05249569, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatically and if tumor reassessment can be performed within a short period.
Interventions
- DRUG Axitinib
- DRUG Avelumab
- DRUG Bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05249569
The ClinicalTrials.gov registry entry for NCT05249569 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Axitinib is the first listed.
NCT05249569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05249569 about?
NCT05249569 is a clinical study titled "Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma". Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatic...
What is the current status of trial NCT05249569?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-11-04. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT05249569?
The interventions under investigation include: Axitinib (DRUG), Avelumab (DRUG), Bavituximab (DRUG).
Who is sponsoring clinical trial NCT05249569?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.